Drugs / CART19 cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03685786 | Jun 2018 → Jun 2021 | B-cell acute lymphoblastic leukemia, B-cell chronic lymphocytic leukemia | Shenzhen Second People's Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CART19 cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03685786 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor T cells (CART Cells)” NCT03685786 ↗ |
| Route | Intravenous | “administered by IV infusion” NCT03685786 ↗ |
| Target | CD19 | “CD19-directed Chimeric Antigen Receptor-modified T (CART19) Cells” NCT03685786 ↗ |